Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT): Comprehensive Research Report

Target for: dismech knowledge-base entry · MONDO:0017990 · Category: Genetic (inherited cardiac ion-channel/calcium-handling disorder / "cardiac channelopathy")

A note on evidence typing throughout (per dismech evidence_source conventions): human cohort/registry/case data = HUMAN_CLINICAL; knock-in mouse / large-animal work = MODEL_ORGANISM; hiPSC-cardiomyocyte, lipid-bilayer, and myocyte studies = IN_VITRO; computational myocyte models = COMPUTATIONAL.

1. Disease Information

Overview. CPVT is a rare, potentially lethal inherited arrhythmia syndrome (cardiac "channelopathy" of intracellular calcium handling) characterized by adrenergically triggered bidirectional and polymorphic ventricular tachycardia (VT) occurring in a structurally normal heart with a normal resting ECG. Arrhythmia is provoked by physical exertion or acute emotion (catecholamine surge) and manifests clinically as exercise/stress-induced syncope, seizures (misdiagnosed as epilepsy), or aborted/actual sudden cardiac death (SCD), typically in children and adolescents. The pathognomonic rhythm is bidirectional VT — a beat-to-beat ~180° alternation of the QRS axis — although polymorphic VT and catecholamine-induced supraventricular arrhythmias also occur.

The syndrome was first defined clinically by Coumel (1978) and characterized in a landmark case series by Leenhardt et al., 1995 (Circulation 91:1512–1519, PMID:7867192), which established the exercise-reproducible bidirectional VT phenotype, childhood onset, and high lethality.

Key identifiers. - MONDO: MONDO:0017990 (catecholaminergic polymorphic ventricular tachycardia) - OMIM (locus/subtype series): CPVT1 #604772 (RYR2); CPVT2 #611938 (CASQ2); CPVT3 #614021 (TECRL locus / older mapping); CPVT4 #614916 (CALM1); CPVT5 #615441 (TRDN). Gene entries: RYR2 180902, CASQ2 114251. - Orphanet: ORPHA:3286 (Catecholaminergic polymorphic ventricular tachycardia). - ICD-10: I47.2 (Ventricular tachycardia — no CPVT-specific code). ICD-11: BC71.0 / arrhythmia block (no dedicated CPVT stem; coded under ventricular tachyarrhythmia + genetic modifier). - MeSH: indexed under Tachycardia, Ventricular (D017180); CPVT exists as a MeSH Supplementary Concept Record ("Ventricular Tachycardia, Catecholaminergic Polymorphic").

Common synonyms / alternative names: Catecholaminergic polymorphic ventricular tachycardia; familial polymorphic ventricular tachycardia (FPVT); bidirectional tachycardia induced by catecholamines; catecholamine-induced polymorphic ventricular tachycardia; stress-induced polymorphic ventricular tachycardia; CPVT.

Data derivation. Information is predominantly from aggregated disease-level resources (GeneReviews, OMIM, Orphanet, ClinGen expert-panel curation) and multicenter registries/cohorts rather than EHR-derived individual-patient datasets, reflecting the disorder's rarity. Key registries: the international CPVT registries feeding Hayashi et al. 2009, van der Werf et al. 2011, and the pediatric CPVT registry (Roston et al. 2015).

2. Etiology

Primary cause — genetic. CPVT is a monogenic Mendelian disorder of cardiomyocyte sarcoplasmic-reticulum (SR) calcium handling. Pathogenic variants dysregulate diastolic SR Ca²⁺ release, so the "trigger" is not the gene alone but catecholaminergic (β-adrenergic) stimulation acting on a genetically primed calcium-release apparatus. There is no structural, ischemic, or inflammatory substrate.

ClinGen-validated causal genes (Gene–Disease Validity): - RYR2 (cardiac ryanodine receptor 2) — CPVT1, autosomal dominant, gain-of-function; ~50–60% of clinically definite cases. - CASQ2 (calsequestrin 2) — CPVT2, classically autosomal recessive (dominant/compound-het forms reported); ~2–5%. - TRDN (triadin) — autosomal recessive; ~1–2%. - CALM1, CALM2, CALM3 (calmodulin) — autosomal dominant "calmodulinopathy"; ~1%, often severe, early-onset, overlapping with LQTS. - TECRL (trans-2,3-enoyl-CoA reductase-like) — autosomal recessive; CPVT/LQTS overlap phenotype.

Genotype-negative fraction: ~30–40% of clinically definite CPVT remains genetically unexplained after testing the known genes (locus/mechanistic heterogeneity; some carry non-coding or copy-number RYR2 variants missed by standard panels).

Risk factors. - Genetic risk (causal): Heterozygous RYR2 gain-of-function missense variants clustered in mutational "hotspots" (N-terminal domain, central domain, C-terminal channel/pore domain); biallelic CASQ2/TRDN/TECRL; dominant CALM variants. Family history of exertional syncope or premature/unexplained SCD is a major risk marker. - Modifier/susceptibility loci: variant location within RyR2 domains and specific residues modulate penetrance and severity (see §4). - Environmental/physiologic "risk" (triggers, not causes): exercise, acute emotional stress, catecholamine administration, fever in overlap cases, and competitive/high-intensity physical activity are the principal arrhythmia precipitants. Male sex and younger age at first symptom are associated with worse arrhythmic outcome.

Protective factors. - Pharmacologic (acquired): β-adrenergic blockade (especially nadolol), flecainide, and left cardiac sympathetic denervation are protective by blunting the catecholaminergic trigger / stabilizing RyR2 (see §12). Exercise restriction reduces trigger exposure. - Genetic protective: No robust protective germline allele is established; residual RyR2 function and variant position influence a milder phenotype but are better described as reduced severity than protection.

Gene–environment interaction. CPVT is a paradigm of GxE: the genetic lesion is clinically silent at rest and unmasked by adrenergic drive. β-agonist provocation (exercise/epinephrine) is both the diagnostic maneuver and the disease trigger, and β-blockade neutralizes the environmental arm — a direct, therapeutically exploited gene–environment axis.

3. Phenotypes

CPVT phenotypes are arrhythmic and exertion-dependent; the heart is structurally and (at rest) electrically normal.

Phenotype characteristics. - Age of onset: typically first/second decade; median age at diagnosis/first symptom ~8–12 years (one systematic review: median onset 11 years, IQR 7–14). A subset presents in adulthood (milder variants). - Severity: severe — high risk of cardiac arrest/SCD; among the most malignant of inherited arrhythmia syndromes when untreated. - Progression: episodic/triggered, not degenerative — arrhythmia burden tracks with adrenergic exposure and treatment adequacy; a stepwise progression from isolated PVCs → bidirectional couplets/bigeminy → non-sustained bidirectional VT → sustained polymorphic VT/VF as workload increases on exercise testing. - Frequency among affected: untreated — ~80% syncope, ~30% cardiac arrest; cumulative arrhythmic events remain substantial even on therapy.

Quality-of-life impact: exercise restriction, competitive-sport disqualification, ICD-related psychosocial burden and inappropriate shocks, anxiety, and impact on schooling/employment. No CPVT-specific QoL instrument; generic tools (SF-36, PedsQL, ICD-specific measures) apply.

4. Genetic / Molecular Information

Causal genes and variant landscape.

• RYR2 (hgnc:10484; OMIM 180902; chr1q43). Encodes the ~5,000-residue cardiac ryanodine receptor, the SR Ca²⁺-release channel. CPVT-causing variants are heterozygous, dominant, gain-of-function missense substitutions producing a "leaky" channel. They cluster in three hotspot domains: N-terminal (aa ~44–466), central/FKBP-binding (aa ~2246–2534), and the C-terminal transmembrane/channel-forming/luminal domain (aa ~3778–4959). Landmark identification: Priori et al., 2001, Circulation 103:196–200 (PMID:11208676) and Laitinen et al., 2001. Functional consequence: gain-of-function → lowered threshold for store-overload-induced Ca²⁺ release (SOICR) and diastolic SR Ca²⁺ leak.
• CASQ2 (hgnc:1513; OMIM 114251; chr1p13). Encodes cardiac calsequestrin, the principal SR luminal Ca²⁺-buffer and RyR2 luminal regulator. Loss-of-function, classically biallelic/recessive. Founder discovery: Lahat et al., 2001, Am J Hum Genet 69:1378–1384 (PMID:11704930) — the D307H missense in consanguineous Bedouin families in Israel (a founder mutation). Truncating/null and dominant/compound-het variants also reported (Postma et al., 2002, Circ Res 91:e21–e26).
• TRDN (hgnc:12261; chr6q22). Triadin — anchors CASQ2 to the RyR2/junctin complex at the junctional SR. Recessive loss-of-function; "triadin knockout syndrome" (CPVT + LQT-like). Roux-Buisson et al., 2012, Hum Mol Genet.
• CALM1/2/3 (hgnc:1442/1445/1449). Calmodulin — Ca²⁺ sensor regulating RyR2 (and Cav1.2, KCNQ1). Dominant, often de novo, severe early-onset CPVT/LQTS-overlap "calmodulinopathy." Nyegaard et al., 2012, Am J Hum Genet 91:703–712 (PMID:23040497).
• TECRL (hgnc:27365). Recessive; CPVT/LQTS-overlap phenotype (Devalla et al., 2016, EMBO Mol Med, hiPSC-CM evidence).

Variant classification & type. Per ACMG/AMP, the great majority of pathogenic CPVT alleles are missense; RyR2 gain-of-function is almost exclusively missense (whole-gene deletions/exon copy-number changes cause a distinct RyR2 loss-of-function / "Ca²⁺-release-deficiency" phenotype, not classic CPVT). CASQ2/TRDN include nonsense, frameshift, splice, and missense null alleles. ClinGen and structure-informed Bayesian penetrance models (2024–2025) are refining VUS interpretation using RyR2 cryo-EM domain mapping.

Allele frequency. Pathogenic RYR2 CPVT variants are rare/absent in gnomAD; RYR2 is highly constrained against missense in general population data. The Bedouin CASQ2 D307H shows elevated regional carrier frequency (founder effect).

Somatic vs germline. Germline (inherited or de novo). Some severe pediatric/CALM cases are de novo; germline mosaicism is documented and relevant to recurrence counseling.

Functional consequences. RYR2 = gain-of-function (leaky channel, ↓SOICR threshold, ↑diastolic Ca²⁺ leak). CASQ2/TRDN/TECRL = loss-of-function (reduced SR Ca²⁺ buffering/regulation → functionally analogous diastolic instability). CALM = altered Ca²⁺-dependent RyR2 regulation (gain-of-function-like on the release apparatus). All converge on diastolic SR Ca²⁺ leak.

Modifier genes / genotype–phenotype. RyR2 variant location and specific residue modulate penetrance/severity; C-terminal channel-domain variants tend toward more severe arrhythmia. No large-effect trans-modifier locus is established; polygenic and background-Ca²⁺-handling modifiers are hypothesized.

Epigenetics / chromosomal abnormalities. No established epigenetic mechanism or recurrent chromosomal abnormality; CPVT is a point-mutation/copy-number-of-single-gene disorder. Large RYR2 exonic deletions/duplications underlie a minority (and, when whole-gene, the LOF Ca²⁺-release-deficiency variant).

Suggested gene terms (HGNC, lowercase per dismech): hgnc:10484 RYR2, hgnc:1513 CASQ2, hgnc:12261 TRDN, hgnc:1442/1445/1449 CALM1/2/3, hgnc:27365 TECRL.

5. Environmental Information

CPVT has no toxic, radiation, occupational, or infectious cause. The relevant "environmental" inputs are physiologic adrenergic triggers, not exposures: - Environmental/physical triggers: vigorous exercise, competitive sport, acute emotional stress/fright, and administration of catecholamines/β-agonists (including diagnostic epinephrine/isoproterenol infusion). Fever can unmask arrhythmia in some overlap variants. - Lifestyle factors: high-intensity/competitive athletics increase event risk (basis for exercise-restriction advice); caffeine/stimulants and sympathomimetic drugs are relational triggers to avoid. - Infectious agents: none causal. (Fever from any infection may act as a nonspecific adrenergic trigger.)

6. Mechanism / Pathophysiology

CPVT is the archetypal disorder of triggered activity from delayed afterdepolarizations (DADs) driven by SR calcium overload/leak. The causal chain:

1. Trigger — β-adrenergic stimulation (upstream). Exercise/emotion → catecholamine release → β1-adrenergic → adenylyl cyclase → cAMP → PKA (and CaMKII) phosphorylation of Ca²⁺-handling proteins (RyR2, phospholamban, L-type Ca²⁺ channel), increasing SR Ca²⁺ load and RyR2 open probability.

2. Molecular lesion — leaky RyR2 / defective SR Ca²⁺ buffering. - RYR2 gain-of-function: the channel's threshold for store-overload-induced Ca²⁺ release (SOICR) is lowered, so RyR2 opens spontaneously in diastole as the SR refills — a diastolic SR Ca²⁺ leak. Two mechanistic frameworks (complementary, sometimes debated): (a) FKBP12.6/calstabin2 destabilization — PKA hyperphosphorylation dissociates the stabilizing subunit, "unzipping"/hyperactivating the channel (Wehrens et al., 2003, Cell 113:829–840, PMID:12809615); (b) defective SOICR/luminal Ca²⁺ regulation — mutation lowers the luminal Ca²⁺ threshold for spontaneous opening (Jiang et al., 2004, PNAS 101:13062–13067, S.R.W. Chen lab). Post-translational oxidation and CaMKII phosphorylation further sensitize the channel. - CASQ2/TRDN loss-of-function: reduced luminal Ca²⁺ buffering and impaired luminal RyR2 regulation destabilize the closed state — same end effect (diastolic Ca²⁺ leak, reduced SR content, premature release).

3. Cellular event — DADs and triggered activity (core). Diastolic cytosolic Ca²⁺ rise activates the electrogenic Na⁺/Ca²⁺ exchanger (NCX1/SLC8A1), which extrudes 1 Ca²⁺ for 3 Na⁺ influx, generating a net inward transient (I_ti) → membrane delayed afterdepolarization. When a DAD reaches threshold it fires a triggered action potential → premature ventricular beat.

4. Tissue-level — bidirectional/polymorphic VT (downstream). Spatially heterogeneous DAD-triggered ectopy from Purkinje/fascicular and ventricular myocardium with alternating beat-to-beat origins produces the hallmark bidirectional VT (≈180° QRS-axis alternans), degenerating into polymorphic VT and ventricular fibrillation → syncope / sudden cardiac death. The Purkinje network is implicated as a key source of triggered beats. Recent optical/computational work shows subthreshold DADs disrupt ventricular activation (RyR2-R420Q models, 2024–2025).

Molecular pathways / GO & cell/anatomy terms. - Biological processes (GO): GO:0055117 regulation of cardiac muscle contraction; GO:0051209 / GO:0014808 release of sequestered Ca²⁺ into cytosol (SR); GO:0060314 regulation of ryanodine-sensitive Ca²⁺-release channel activity; GO:0051924 regulation of Ca²⁺ transport; GO:0086002/GO:0086005 cardiac muscle cell action potential / ventricular cardiac muscle cell action potential; GO:0006816 calcium ion transport. - Molecular functions (GO): GO:0005219 ryanodine-sensitive Ca²⁺-release channel activity; GO:0005509 calcium ion binding; GO:0015085 calcium ion transmembrane transporter activity (NCX). - Cellular components (GO): GO:0033017 sarcoplasmic reticulum membrane; GO:0016529 sarcoplasmic reticulum; GO:0014701 junctional SR membrane; GO:0030315 T-tubule. - Cell types (CL): CL:0000746 cardiac muscle cell (cardiomyocyte); CL:0002098 regular ventricular cardiac myocyte; CL:0002068 Purkinje myocyte (cardiac conduction). - Anatomy (UBERON): UBERON:0002349 myocardium; UBERON:0002084 heart left ventricle; UBERON:0002094 interventricular septum; UBERON:0002351 Purkinje fiber network; UBERON:0000948 heart; UBERON:0002061 sinoatrial node (bradycardia arm). - Chemicals (CHEBI): CHEBI:29108 calcium(2+); CHEBI:17489 cyclic AMP; CHEBI:29101 sodium(1+); catecholamines CHEBI:33569 noradrenaline / CHEBI:28918 adrenaline.

Metabolic/immune involvement: none — CPVT is not metabolic, inflammatory, or autoimmune. No energy-metabolism or immune mechanism; "tissue damage" is functional/electrical, not necrotic/fibrotic (heart is structurally normal).

-omics. hiPSC-derived cardiomyocytes from CPVT patients robustly recapitulate DADs/spontaneous Ca²⁺ release and are a primary IN_VITRO platform (e.g., patient-specific RyR2 lines; TECRL Devalla 2016). Single-cell Ca²⁺-imaging and computational myocyte models (Guinea-pig/human) quantify SOICR thresholds and pacing-dependent arrhythmogenesis.

7. Anatomical Structures Affected

• Organ level (primary): heart (UBERON:0000948) — specifically ventricular myocardium (UBERON:0002349) and the cardiac conduction/Purkinje system (UBERON:0002351); left ventricle (UBERON:0002084). Structurally normal by imaging; the defect is functional/electrical.
• Secondary/system involvement: cardiovascular system; secondary CNS effects (syncope, hypoxic seizure) are consequences of transient arrhythmic cerebral hypoperfusion, not primary CNS disease. Autonomic nervous system (sympathetic cardiac innervation) is the trigger pathway and the target of sympathetic denervation therapy.
• Tissue/cell level: cardiac muscle tissue; affected cell populations = ventricular cardiomyocytes (CL:0002098) and Purkinje myocytes (CL:0002068); atrial myocytes/SA-node cells account for supraventricular arrhythmia and bradycardia components.
• Subcellular level (GO cellular component): sarcoplasmic reticulum (GO:0016529) and junctional SR membrane (GO:0014701); T-tubule (GO:0030315); dyadic cleft RyR2–L-type-channel couplon; sarcolemma/plasma membrane (NCX, β-receptor).
• Localization/lateralization: biventricular/global myocardial process (not lateralized); therapeutically, the left stellate/thoracic sympathetic chain is targeted (left cardiac sympathetic denervation), reflecting left-dominant sympathetic influence on ventricular arrhythmogenesis.

8. Temporal Development

• Onset: typically childhood/adolescence (first/second decade); median first symptom/diagnosis ~8–12 years (systematic-review median 11 y). Rare congenital/infantile presentations (CALM, severe RYR2). Adult-onset milder forms exist. Onset pattern of symptoms is acute/episodic (event-driven), on a lifelong genetic substrate.
• Progression / course: lifelong, episodic/triggered, not neurodegenerative-style progressive. Within an exercise test, arrhythmia shows a reproducible, graded escalation (isolated PVCs → bigeminy/couplets → non-sustained → sustained bidirectional/polymorphic VT) above a threshold heart rate (~110–130 bpm). Untreated natural history is malignant (early cardiac arrest/SCD).
• Patterns: no spontaneous remission; treatment-induced control (β-blockade/flecainide/LCSD) is the goal. Critical intervention window: early diagnosis (often after a first syncope/aborted arrest or via family cascade screening) before a fatal event — the strongest determinant of outcome. Untreated cumulative mortality reaches ~30–50% by the third–fourth decade.

9. Inheritance and Population

Epidemiology. - Prevalence: estimated ~1 in 10,000 (Orphanet/GeneReviews). True prevalence likely underestimated (sudden death may be the first event; normal resting ECG defies routine screening). - Incidence: not precisely established (rare disease); CPVT is a recognized cause of autopsy-negative sudden unexplained death in the young / SIDS-adjacent cases and drives a share of "idiopathic" exercise-related SCD.

Genetic parameters. - Inheritance pattern: autosomal dominant — RYR2, CALM1/2/3, KCNJ2-associated (Andersen–Tawil overlap); autosomal recessive — CASQ2 (classic), TRDN, TECRL (dominant/compound-het CASQ2 also occur). De novo variants common in severe pediatric/CALM cases. - Penetrance: overall clinical penetrance ~70–80% (range reported 25–100%); RYR2 mean penetrance ~83%; biallelic CASQ2 essentially 100% penetrant in reported individuals. Structure-informed Bayesian models (2024–2025) show penetrance varies continuously by RyR2 domain/residue. - Expressivity: variable — from asymptomatic exercise-test-positive carriers to childhood cardiac arrest, even within a family. - Anticipation: not a feature (no repeat expansion). - Germline mosaicism: documented; relevant to recurrence risk when a proband appears "de novo." - Founder effects: CASQ2 D307H founder mutation in Bedouin Israeli families (Lahat 2001); other regional CASQ2/RYR2 founder alleles reported. - Consanguinity: relevant for recessive CASQ2/TRDN/TECRL (consanguineous pedigrees). - Carrier frequency: low; elevated regionally for founder alleles.

Population demographics. - Affected populations: panethnic; recessive founder clusters in consanguineous populations (Bedouin, other Middle Eastern/North African). - Sex ratio: roughly balanced overall; some cohorts show female predominance in ascertained series (systematic review 351 M / 463 F), but male sex is associated with worse arrhythmic outcome/earlier events. Gender-related inheritance-mode differences in RYR2 transmission have been reported. - Age distribution: skewed young (index events predominantly in children/adolescents/young adults).

10. Diagnostics

Core diagnostic approach: demonstrate reproducible exercise/catecholamine-induced ventricular ectopy/bidirectional or polymorphic VT in the setting of a normal resting ECG and structurally normal heart, plus genetic confirmation and family history.

• Resting ECG: typically normal (sometimes sinus bradycardia, prominent U waves); QT normal (distinguishes from LQTS).
• Exercise stress testing (cornerstone): graded treadmill/bicycle test reproducibly provokes, above a threshold HR, PVCs → ventricular bigeminy/couplets → non-sustained → bidirectional/polymorphic VT. Highly reproducible; used for diagnosis and treatment monitoring. LOINC: standard exercise stress ECG panels.
• Ambulatory (Holter) / event / implantable loop monitoring: captures exertion-related ectopy and supraventricular arrhythmias.
• Epinephrine or isoproterenol provocation: pharmacologic catecholamine challenge when exercise testing is not feasible (lower sensitivity/specificity than exercise).
• Echocardiography / cardiac MRI: to confirm structural normality and exclude ARVC, myocarditis, ischemia, sarcoid.
• Electrophysiology: programmed stimulation is generally not useful (does not reliably induce CPVT VT — a distinguishing feature).
• Biomarkers/labs: none diagnostic; used to exclude ischemia/electrolyte causes.

Genetic testing. - Recommended approach: targeted CPVT/arrhythmia multigene panel covering RYR2, CASQ2, TRDN, CALM1/2/3, TECRL (± KCNJ2), with RYR2 as the highest-yield single gene (~50–60%). WES/WGS reserved for panel-negative cases; CNV/exon-level analysis of RYR2 is important (missed by some panels). - Cascade family screening: predictive testing of first-degree relatives for a known familial variant is central to management; clinically-driven (exercise testing) screening for genotype-negative families. - Not applicable: karyotype/FISH/CMA (single-gene disorder), mitochondrial DNA, repeat-expansion testing.

Clinical diagnostic criteria. Per HRS/EHRA/APHRS 2013 expert consensus (Priori et al.) and ESC 2022 Guidelines on ventricular arrhythmias/SCD (Zeppenfeld et al., Eur Heart J 2022): CPVT is diagnosed by (i) structurally normal heart + normal ECG + exercise/emotion-induced bidirectional/polymorphic VT in a person <40 y; or (ii) a pathogenic variant in a CPVT gene; or (iii) exercise-induced bidirectional/polymorphic VT in a family member of a CPVT proband.

Differential diagnosis: Long QT syndrome (esp. LQT1/LQT7 Andersen–Tawil, LQT with catecholamine sensitivity), Andersen–Tawil syndrome (KCNJ2), ARVC, idiopathic VF, digoxin toxicity (bidirectional VT), Timothy syndrome, and structural/ischemic VT.

11. Outcome / Prognosis

• Untreated natural history is malignant: ~80% syncope, ~30% cardiac arrest, and substantial early mortality (cumulative death/aborted-arrest reaching ~30–50% by age 30–40); SCD may be the sentinel event.
• With treatment: high-dose non-selective β-blockade (nadolol) markedly reduces mortality; addition of flecainide and/or LCSD further lowers arrhythmic events, though a residual life-threatening arrhythmia burden persists in a minority even on optimal therapy — hence ICD for refractory/high-risk patients.
• Prognostic factors (worse outcome): younger age at first symptom, cardiac arrest as presenting event, male sex, absence of/poor adherence to β-blockade, arrhythmia inducibility despite therapy on exercise testing, and specific RYR2 variant classes/locations. Persistent exercise-test-inducible complex ectopy on therapy is a key risk marker; suppression is a treatment goal.
• Morbidity: exercise restriction, ICD-related complications (inappropriate shocks — β-blockers reduce these), anxiety/psychosocial burden, and risk of arrhythmic syncope-related injury.
• Recovery potential: the substrate is lifelong; "recovery" = durable arrhythmia suppression, not cure (gene therapy aims to change this — §12).

12. Treatment

Pharmacotherapy. - β-blockers (first-line, all symptomatic and most genotype-positive patients). Non-selective β-blockers are superior; nadolol is the preferred agent (long half-life, best evidence): nadolol ~1–2.5 mg/kg/day; propranolol ~2–4 mg/kg/day as alternative. MAXO: MAXO:0000058 (pharmacotherapy) / drug class NCIT beta-adrenergic antagonist; agent CHEBI nadolol (CHEBI:7439), propranolol (CHEBI:8499). Mechanism: blunts the catecholaminergic trigger. - Flecainide (second-line add-on / and increasingly early combination). Directly inhibits RyR2 Ca²⁺ release and blocks Na⁺ current, suppressing DAD-triggered beats. Efficacy shown in mice and humans: Watanabe et al., 2009, Nat Med 15:380–383 (PMID:19330009) and van der Werf et al., 2011, J Am Coll Cardiol 57:2244–2254 (PMID:21616285). Add for breakthrough arrhythmia on β-blockade or up front in high-risk patients. CHEBI flecainide CHEBI:4956. (Mexiletine is an alternative Na⁺-channel adjunct in some overlap cases.) - Pharmacogenomics: treatment is genotype-informed at the syndrome level (RYR2-leak biology → flecainide rationale); no established CYP-based dosing mandate, though flecainide is CYP2D6-metabolized (relevant to levels).

Device / interventional / surgical. - Left cardiac sympathetic denervation (LCSD) — removal/ablation of the left stellate ganglion (lower half) + T2–T4 thoracic ganglia; antiadrenergic adjunct for patients with breakthrough events on medical therapy or ICD-shock storms (Wilde et al., 2008, N Engl J Med 358:2024–2029, PMID:18463378). Bilateral/right-sided denervation reported in refractory cases. MAXO: MAXO:0000004 (surgical procedure). - Implantable cardioverter-defibrillator (ICD) — for aborted cardiac arrest / refractory arrhythmia despite optimal drug therapy ± LCSD (secondary prevention; selective primary prevention). Caveat: ICD shocks can be proarrhythmic in CPVT (shock-induced catecholamine surge → arrhythmic storm), so must be combined with maximal β-blockade, programmed with long delays, and is not a substitute for pharmacotherapy. MAXO: implantation of cardioverter-defibrillator. - Catheter ablation of a triggering PVC focus (e.g., Purkinje) is investigational/adjunctive in selected refractory cases.

Lifestyle / supportive. Restriction of competitive and high-intensity exercise, avoidance of sympathomimetic drugs/stimulants, treatment of triggers, and genetic counseling/family cascade screening are integral. MAXO: behavioral/lifestyle intervention.

Experimental / advanced therapeutics (RNA & gene therapy — active 2023–2025 pipeline). - AAV-CASQ2 gene replacement (SGT-501, Solid Biosciences; originating from the Priori/ICS Maugeri Pavia lab). Delivers a codon-optimized full-length CASQ2 to cardiomyocytes; increased calsequestrin improves SR Ca²⁺ buffering and stabilizes RyR2. Preclinical CASQ2-knock-in mice showed durable, potentially curative rescue with single systemic AAV delivery. FDA Fast Track designation; first-in-human Phase 1b initiated ~2024–2025. (MODEL_ORGANISM preclinical → early HUMAN_CLINICAL.) - RYR2-targeted approaches: allele-specific silencing/CRISPR editing and RyR2-stabilizing small molecules (e.g., dantrolene, S107/"rycals" targeting FKBP12.6 binding) under preclinical/early investigation. - Suggested treatment/modality tags (dismech): therapeutic_modality: GENE_THERAPY (AAV-CASQ2), SMALL_MOLECULE (nadolol, flecainide), SURGERY (LCSD), DEVICE (ICD), BEHAVIORAL (exercise restriction).

Treatment strategy / algorithm (ESC 2022 / HRS 2013 consensus): (1) β-blocker (nadolol) for all symptomatic and most genotype-positive patients + exercise restriction; (2) add flecainide for breakthrough arrhythmia (or up front in high-risk); (3) LCSD for persistent events / ICD-shock burden; (4) ICD for aborted arrest/refractory disease, always on maximal β-blockade; (5) cascade family screening; (6) emerging gene therapy for genetically defined (CASQ2) disease.

13. Prevention

• Primary prevention: not preventable at the population level (genetic). Prevention = pre-symptomatic identification via family cascade genetic/exercise screening of relatives of a proband, then prophylactic β-blockade + exercise restriction in genotype-positive individuals. Avoidance of adrenergic triggers (competitive sport, sympathomimetics).
• Secondary prevention: early diagnosis after a first syncope/aborted arrest; exercise stress testing as the key detection tool; treat before a fatal event.
• Tertiary prevention: escalate therapy (flecainide, LCSD, ICD) to prevent recurrent arrhythmia/SCD; adherence support; ICD shock-storm avoidance via β-blockade.
• Genetic counseling: autosomal-dominant (RYR2/CALM) vs recessive (CASQ2/TRDN/TECRL) recurrence risk; de novo/mosaicism counseling; predictive testing of minors is justified (early treatment prevents death). Reproductive options: prenatal testing and preimplantation genetic testing (PGT) available for known familial variants.
• Public/behavioral: athlete pre-participation awareness, family SCD history taking, AED access, CPR training for families; no immunization/environmental measures apply.

14. Other Species / Natural Disease

• Taxonomy of models/natural disease: primarily studied in Mus musculus (NCBITaxon:10090); naturally occurring analogues reported in domestic species.
• Orthologous genes: Ryr2, Casq2, Trdn, Calm1/2/3, Tecrl are conserved across mammals (NCBI Gene orthologs in mouse/rat/dog).
• Natural disease: German Shepherd dogs exhibit an inherited ventricular-arrhythmia/SCD syndrome with catecholaminergic features studied as a large-animal model of ventricular arrhythmia; exercise/catecholamine-triggered ventricular arrhythmias occur in veterinary cardiology. (OMIA is the resource for animal Mendelian correlates.)
• Comparative biology: RyR2/CASQ2 Ca²⁺-handling and DAD/SOICR mechanisms are evolutionarily conserved, making cross-species models highly translational; species differences in heart rate and Ca²⁺-handling kinetics require caution when extrapolating triggering thresholds.
• Transmission: not applicable (non-communicable, no zoonotic potential).

15. Model Organisms

Mouse (principal model). - RYR2 knock-in models: RyR2-R4496C (Cerrone et al., 2005) — the classic CPVT1 mouse; exercise/catecholamine-inducible bidirectional VT, DADs, faithful phenotype recapitulation. Other knock-ins: R2474S, R176Q, R420Q (used in recent activation-mapping/optical studies). - CASQ2 models: Casq2-null / Casq2-D307H knock-in mice reproduce CPVT2 with catecholamine-induced VT — the platform for AAV-CASQ2 gene-therapy rescue studies (durable, near-curative correction). - Triadin/TECRL/CALM knockout/knock-in models reproduce respective phenotypes.

Model characteristics. Mouse knock-ins strongly recapitulate the human phenotype (structurally normal heart, catecholamine/exercise-inducible bidirectional/polymorphic VT, cardiomyocyte DADs, spontaneous SR Ca²⁺ release) — hence high validity. Limitations: murine heart rate/electrophysiology differ from human; bidirectional VT morphology is less consistent; sudden-death rates and drug pharmacokinetics require careful translation.

Cellular / in vitro models (IN_VITRO). - Patient-specific hiPSC-derived cardiomyocytes (RYR2, CASQ2, TECRL) reliably show DADs and abnormal diastolic Ca²⁺ release upon catecholamine challenge — used for mechanism, variant functional classification, and drug screening (e.g., flecainide response; Devalla 2016 TECRL). - Heterologous expression (HEK293/lipid bilayer) of mutant RyR2 for single-channel SOICR/gating studies. - Isolated cardiomyocyte Ca²⁺ imaging and computational myocyte models (guinea-pig/human ventricular) quantifying SOICR thresholds and pacing-dependent DAD/triggered activity.

Applications. Mechanistic dissection (SOICR vs FKBP12.6), preclinical testing of β-blockers/flecainide/rycals, and AAV gene-therapy proof-of-concept (CASQ2 rescue) that seeded the current clinical program. Resources: MGI/IMSR (mouse strains), Cellosaurus (hiPSC lines), Alliance of Genome Resources (orthology), OMIA (animal correlates).

Key Citations (verify each PMID against the abstract before quoting in a KB YAML snippet:)

Landmark / mechanistic - Leenhardt A, et al. Circulation 1995;91:1512–1519 — original clinical CPVT series. PMID:7867192 - Priori SG, et al. Circulation 2001;103:196–200 — RYR2 mutations cause CPVT1. PMID:11208676 - Lahat H, et al. Am J Hum Genet 2001;69:1378–1384 — CASQ2 D307H founder (Bedouin), CPVT2. PMID:11704930 - Priori SG, et al. Circulation 2002;106:69–74 — RYR2 clinical–genetic characterization. PMID:12093772 - Wehrens XHT, et al. Cell 2003;113:829–840 — FKBP12.6/calstabin2 destabilization mechanism. PMID:12809615 - Nyegaard M, et al. Am J Hum Genet 2012;91:703–712 — CALM1 in CPVT. PMID:23040497

Treatment / outcome - Wilde AAM, et al. N Engl J Med 2008;358:2024–2029 — LCSD in CPVT. PMID:18463378 - Hayashi M, et al. Circulation 2009;119:2426–2434 — natural history/outcomes. PMID:19398665 - Watanabe H, et al. Nat Med 2009;15:380–383 — flecainide blocks RyR2, suppresses CPVT (mouse + human). PMID:19330009 - van der Werf C, et al. J Am Coll Cardiol 2011;57:2244–2254 — flecainide clinical efficacy. PMID:21616285

Guidelines / consensus / recent - Zeppenfeld K, et al. 2022 ESC Guidelines for ventricular arrhythmias and prevention of SCD, Eur Heart J 2022. - Priori SG, et al. HRS/EHRA/APHRS Expert Consensus on inherited primary arrhythmia syndromes, 2013. - GeneReviews — Catecholaminergic Polymorphic Ventricular Tachycardia (Napolitano, Mazzanti, Priori et al.), NCBI Bookshelf NBK1289 (gene fractions, penetrance, prevalence). - Recent reviews (2023–2025): RYR2-ryanodinopathies (Europace 2023, euad156); JAHA 2024 "Molecular Insights to Preclinical Models" (JAHA.124.038308); J Clin Med 2024;13(6):1781; Circ Arrhythm Electrophysiol 2024–2025 RYR2 structure–penetrance studies.

Sources (web-verified during this research): - MDPI J Clin Med 2024 — CPVT clinical/diagnostic/therapeutic review - Precision medicine in CPVT (PMC11135882) - JAHA 2024 — CPVT: Molecular Insights to Preclinical Models - GeneReviews — CPVT (NBK1289) - ClinGen Actionability summary — CPVT - CPVT: an update (PMC6931575) - RYR2-ryanodinopathies: calcium overload to deficiency (Europace, PMC10311407) - Frontiers 2022 — Molecular changes in RyR2 with CPVT (PMC8867003) - Lahat et al. 2001 — CASQ2 Bedouin founder (ScienceDirect) - OMIM 114251 — CASQ2 - Solid Biosciences SGT-501 AAV-CASQ2 gene therapy — Phase 1b - FDA Fast Track for SGT-501 (Contemporary Pediatrics) - Gene Therapy for CPVT (PMC5902314) - Heart Rhythm 2024 — Top stories on CPVT 2022–2024 - RYR2 variants: protein structure & clinical data (Circ AE; PubMed 40875405) - Structural evaluation of RYR2-CPVT variants & Bayesian penetrance (PMC11957170)

Curation handoff notes (dismech-specific)

When loading this into kb/disorders/Catecholaminergic_Polymorphic_Ventricular_Tachycardia.yaml: 1. This entry is a strong conformer to the existing cardiac_ion_channel_repolarization module — specifically the #Arrhythmogenic Substrate and Triggered Activity node (declare conforms_to), and it is a listed candidate/member of the Inherited_Arrhythmia_Syndromes grouping. Note the module's framing is "structurally normal hearts… RYR2-CPVT" — CPVT fits its calcium-handling/triggered-activity arm. 2. Every snippet must be an exact abstract substring — run just fetch-reference PMID:XXXX then just validate-references before commit; do not paste the paraphrased search-summary text above as snippets. 3. Verify all ontology terms (just validate-terms-file) — I've suggested HP/GO/CL/UBERON/CHEBI IDs from memory; confirm labels via OAK (e.g., HP:0004758 bidirectional VT, HP:0031677 polymorphic VT) before binding. 4. Model MOI explicitly per gene (AD RYR2/CALM vs AR CASQ2/TRDN/TECRL); the digenic pattern does not apply here, but multi-gene locus heterogeneity does. 5. Tag AAV-CASQ2 as therapeutic_modality: GENE_THERAPY and add the SGT-501 trial as a clinical_trials entry (fetch the NCT ID and validate against ClinicalTrials.gov).